Clinical trials: Anxiety, Generalized
Generalized Anxiety Disorder
A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone
Generalized anxiety disorder (GAD) is usually treated with antidepressant therapy (ADT); however, sometimes ADTs alone are not enough to adequately treat GAD.
- Trial name
- CAR aGAD Ph 2 (NCT04965272)
- Testing
- Cariprazine 0.75 mg/day, Cariprazine 1.5 mg/day, Cariprazine 3.0 mg/day
- Where
- 36 sites in United States
- Sponsor
- AbbVie
Generalized Anxiety Disorder
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic…
- Trial name
- NCT06480383
- Testing
- ITI-1284 10 mg, ITI-1284 20 mg
- Where
- 56 sites in United States, Bulgaria and 3 more
- Volunteers
- 705 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Post-traumatic Stress Disorder (PTSD)
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline
- Trial name
- NCT05189977
- Testing
- Propranolol, Prazosin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo in Generalized Anxiety Disorder
The purpose of this study is to demonstrate that quetiapine SR (SEROQUEL®) is efficacious and safe in the acute treatment of patients with Generalized Anxiety Disorder.
- Trial name
- TITANIUM (NCT00329264)
- Testing
- Quetiapine fumarate
- Where
- 58 sites in United States
- Volunteers
- 876 people
- Sponsor
- AstraZeneca
Anxiety
Probiotics for Anxiety Study
The purpose of this study is to observe the effect of a consumer-grade probiotic capsule called GABA (gamma-aminobutyric acid ) Probiotic ("Study Product"), a probiotic capsule containing Lactiplantibacillus plantarum 815, on…
- Trial name
- NCT06466603
- Testing
- GABA Probiotic Dose 1, GABA Probiotic Dose 2
- Where
- United States
- Volunteers
- 122 people, healthy volunteers welcome
- Sponsor
- Verb Biotics LLC
Generalized Anxiety Disorder
A 10-Week Study for Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00236067
- Testing
- Gabitril
- Where
- 21 sites in United States
- Volunteers
- 440 people
- Sponsor
- Cephalon
Social Anxiety Disorder
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
This trial will explore the efficacy of quetiapine in Social Anxiety Disorder, generalized type. The following elements of response will be tested: number of responders to treatment, time to response, effect size as measured with…
- Trial name
- NCT00302770
- Testing
- quetiapine
- Where
- Netherlands
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Pain, Depression
Study Evaluating Rhapsody Registry in Patients With Depression and Anxiety
The purpose of this study is to assess the prevalence of Major Depression and/or Anxiety Disorder in patients consulting the General Practitioner with acute or chronic painful physical symptoms and to identify risk factors.
- Conditions
- Pain, Depression, Anxiety Disorder
- Trial name
- NCT00241397
- Where
- 91 sites in Belgium
- Volunteers
- 2,560 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Schizophrenia, Major Depressive Disorder
PHARMO Institute Seroquel Safety Study
The purpose of this observational study is to study specific outcomes of interest in users of quetiapine compared with all other atypical antipsychotics and specifically olanzapine and risperidone.
- Conditions
- Schizophrenia, Major Depressive Disorder, Bipolar Disorder, Generalized Anxiety Disorder
- Trial name
- PHARMO II (NCT01342120)
- Volunteers
- 18,325 people
- Sponsor
- AstraZeneca
Generalized Anxiety Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.
The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.
- Trial name
- NCT00744627
- Testing
- Vortioxetine
- Where
- 38 sites in Estonia, Germany and 6 more
- Volunteers
- 301 people
- Sponsor
- Takeda
Anxiety Disorders
Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder
This study will test the efficacy, safety and tolerability of XBD173 in the treatment of generalized anxiety disorder in patients.
- Trial name
- NCT00108836
- Testing
- XBD173
- Where
- 23 sites in United States, Canada
- Volunteers
- 400 people
- Sponsor
- Novartis Pharmaceuticals
Generalized Anxiety Disorder
An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder
The purpose of this study is to determine the safety and efficacy of vortioxetine, once daily (QD), in treating Generalized Anxiety Disorder.
- Trial name
- NCT00734071
- Testing
- Vortioxetine
- Where
- 33 sites in United States
- Volunteers
- 304 people
- Sponsor
- Takeda
General Anxiety Disorder
Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Anxiety in Adolescents
Trial title: A Randomized, Double-blind Sham-controlled Clinical Trial to Evaluate The Efficacy of Electrical Vestibular Stimulation (VeNS), Compared to a Sham Control For The Management Of Anxiety in Adolescents - The Modius…
- Trial name
- NCT06956105
- Testing
- Modius Calm
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Neurovalens Ltd.
Generalized Anxiety Disorder
A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects ages 18 and older with generalized anxiety disorder.
- Trial name
- NCT00658762
- Testing
- PD 0332334, paroxetine
- Where
- 28 sites in United States, Hungary
- Volunteers
- 286 people
- Sponsor
- Pfizer
Anxiety, Obsessive-Compulsive Disorder
Virtual Reality System for Anxiety and OCD
Cognitive Behavioral Therapy with fear provoking exposures is the most effective therapy for anxiety disorders. The investigators aim to enhance this therapy with the use of virtual reality exposures.
- Trial name
- NCT03636022
- Testing
- VR System, Control
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Minnesota HealthSolutions
Generalized Anxiety Disorder
Duloxetine for the Treatment of Generalized Anxiety Disorder
This is a 15 week study comparing how well duloxetine and placebo treatments improve generalized anxiety disorder
- Trial name
- NCT00803361
- Testing
- Duloxetine
- Where
- 7 sites in China
- Volunteers
- 210 people
- Sponsor
- Eli Lilly and Company
Generalized Anxiety Disorder (GAD)
Device for Treating Generalized Anxiety
The goal of this clinical trial is to learn if treatment with the BTL-699-2 device (non-invasive repetitive transcranial magnetic stimulation) can decrease anxiety symptoms in adults (aged 22 years and older) diagnosed with…
- Trial name
- NCT07819773
- Testing
- EXOMIND (BTL-699-2) Active treatment
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- BTL Industries Ltd.
Generalized Anxiety Disorder
Efficacy and Safety of Pregabalin vs Placebo for Generalized Anxiety Disorder (GAD) Symptoms in Subjects Discontinuing Benzodiazepine Treatment and Remaining 6 Weeks on Study Medication, Free From Benzodiazepine Use.
GAD subjects maintained on a stable dose of alprazolam for at least four weeks who meet eligibility criteria will be randomized to receive pregabalin vs matching placebo while simultaneously tapering off of alprazolam over 6…
- Trial name
- GAD (NCT00368745)
- Testing
- Pregabalin
- Where
- 21 sites in Costa Rica, Czechia and 5 more
- Volunteers
- 108 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Generalized Anxiety Disorder
A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of PD 0332334 compared to placebo in the treatment of Generalized Anxiety Disorder in an adult population
- Trial name
- NCT00921063
- Testing
- PD 0332334, Alprazolam extended release
- Volunteers
- 222 people
- Sponsor
- Pfizer
Anxiety Disorders
Duloxetine Compared With Placebo in the Prevention of Relapse in Generalized Anxiety Disorder
This is a clinical trial assessing the time to relapse of anxiety symptoms among patients with generalized anxiety disorder who have responded to duloxetine therapy.
- Trial name
- NCT00122863
- Testing
- Duloxetine Hydrochloride
- Where
- 47 sites in United States, Austria and 5 more
- Volunteers
- 380 people
- Sponsor
- Eli Lilly and Company